%0 Journal Article
%T Expanded clinical and experimental use of SOX11 - using a monoclonal antibody
%A Lena Nordstr£¿m
%A Ulrika Andr¨¦asson
%A Mats Jerkeman
%A Michael Dictor
%A Carl Borrebaeck
%A Sara Ek
%J BMC Cancer
%D 2012
%I BioMed Central
%R 10.1186/1471-2407-12-269
%X We have developed SOX11-C1, a monoclonal mouse antibody targeting SOX11, and successfully evaluated its performance in western blots (WB), IHC-P, fluorescence microscopy and flow cytometry.We confirm the importance of SOX11 as a diagnostic antigen in MCL as 100% of tissue micro array (TMA) cases show bright nuclear staining, using the SOX11-C1 antibody in IHC-P. We also show that previous reports of weak SOX11 immunostaining in a fraction of hairy cell leukemias (HCL) are not confirmed using SOX11-C1, which is consistent with the lack of transcription. Thus, high sensitivity and improved specificity are demonstrated using the monoclonal SOX11-C1 antibody. Furthermore, we show for the first time that flow cytometry can be used to separate SOX11 positive and negative cell lines and primary tumors. Of note, SOX11-C1 shows no nonspecific binding to primary B or T cells in blood and thus, can be used for analysis of B and T cell lymphomas from complex clinical samples. Dilution experiments showed that low frequencies of malignant cells (~1%) are detectable above background using SOX11 as a discriminant antigen in flow cytometry.The novel monoclonal SOX11-specific antibody offers high sensitivity and improved specificity in IHC-P based detection of MCL and its expanded use in flow cytometry analysis of blood and tissue samples may allow a convenient approach to early diagnosis and follow-up of MCL patients.
%K SOX11
%K Flow cytometry
%K Immunohistochemistry
%K Transcription factor
%K B cell lymphoma diagnostics
%U http://www.biomedcentral.com/1471-2407/12/269/abstract